复星凯特生物科技有限公司成立于2017年，是由复星医药集团与美国Kite Pharma共同设立。Kite Pharma在T细胞免疫治疗领域的研发处于全球领先，而复星医药具有丰富的药品制造,研发投入和商业化经验，并在肿瘤治疗领域拥有多项在研产品。复星凯特合资企业立足于自主研发和技术转移相结合，为中国肿瘤免疫细胞治疗技术的开发和产业化规范化而努力，造福患者。Fosun Kite Biotechnology Co., Ltd (hereinafter referred as "Fosun Kite"), is a joint venture formed in Shanghai China by Fosun Pharma and Kite Pharma. Fosun Kite is dedicated to research and development, via internal effort, collaboration or transferring the world's most advanced cell therapy technologies, including the US approved CAR-T product axicabtagene ciloleucel (Yescarta) for commercialization in China to save patient’s lives.